Zacks Investment Ideas feature highlights: First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Mortgage REIT Income ETF and PowerShares Preferred Portfolio

Zacks

For Immediate Release
 
Chicago, IL- February 05, 2014 – Today, Zacks Investment Ideas feature highlights Features: First Trust NYSE Arca Biotechnology Index Fund (FBT-Free Report), Market Vectors Mortgage REIT Income ETF (MORT-Free Report) and PowerShares Preferred Portfolio (PGX-Free Report).
 
Market Concerns? Try These Resilient ETFs
 
After an amazing 2013, markets are experiencing a bit of a hangover to start the New Year. Worries about the taper along with sluggish economic data—including weakness in both the manufacturing and jobs segments—has pushed stocks sharply lower. In fact, broad markets have fallen by about 5% on the year, erasing much of the strength that investors had seen to end 2013.

Yet while many segments have fallen with the broad markets, a few have shown impressive resiliency, and are actually still up on the year. These segments may thus prove to be solid picks for investors seeking a respite from the market’s current storm, and they could also be great choices for the rest of the year if more turbulence hits the market (see all the Top Ranked ETFs here).

Below, we highlight three such segments—and ETFs to track them—which have not only survived the current market slump, but have actually prospered as well. These funds might have flown under your radar until now, but with their solid performances in what has otherwise been a poor market environment, they could now deserve a place on your watchlist:

Biotech

Despite the downturn, growing segments of the market are still very much in demand. And given some of the recent health care law changes, this is particularly true for the biotech space, as any new drugs look likely to see a huge market, while the potential for M&A activity remains extremely high.

There are a number of ways to play this trend, but the First Trust NYSE Arca Biotechnology Index Fund (FBT-Free Report) is a great choice. This product receives a top Zacks ETF Rank #1 (Strong Buy), and even with Monday’s slump it is easily beating out the S&P 500 over the past month (also see Biotechnology ETF Investing 101).

This product may be a better choice for investors as it is a nice mix between market cap levels thanks to its equal weight method. This puts 50% into the large cap space, making the fund a higher risk choice, but also a biotech that has some stability attached to it, an interesting combination in today’s market environment.
 
Mortgage REITs

Concerns over soaring rates really hit the real estate market hard last year, and especially so in the mortgage REIT space. This segment is usually highly leveraged and increases in rates can have a devastating impact, which is why the recent move lower in benchmark rates benefited this space so much.
One way to play this trend is with the Market Vectors Mortgage REIT Income ETF (MORT-Free Report) which is up almost 4.3% in the past month. The fund, which follows the Market Vectors Global Mortgage REIT Index, also pays out a 30-Day SEC yield approaching 9.8%, so it is a great income destination as well (see all the Real Estate ETFs here).

The product is a bit concentrated in its top names, and it was really hit hard in 2013, losing more than 15% on the year. Still, if rates stabilize near historic-lows this could be an interesting play, especially given the near double-digit yield.
 
Preferred Stock
 
Preferred stock are known for their stability as they have both debt and equity characteristics. They also pay out relatively high yields, so when yields are slumping and risks are piling on, they can attract a great deal of investors.
 
This has certainly been the case as of late, and it is why investors might ‘prefer’ a fund like the PowerShares Preferred Portfolio (PGX-Free Report) in their portfolios. This fund tracks a benchmark of just under 200 preferred stocks, focusing on financials for exposure (see Time for Preferred Stock ETFs?).
 
The fund does a decent job of spreading out assets, as no single security makes up more than 4.2% of the total assets. The yield is also pretty impressive as the 30-Day SEC payout comes in at nearly 6.5%.  
 
Bottom Line
 
Memories of 2013’s market surge are largely disappearing into investors’ rearview mirrors, as worries over the taper and poor jobs and manufacturing data dominate the landscape. A solid earnings season hasn’t been able to stop the slide either, and many segments are well into the red to start 2014 (see Best ETF Strategies for 2014).
 
However, despite the broad gloom, there are a few market segments that have been able to post decent returns to start the year. These have proven to be quite resilient, and thus for investors seeking safety, they might be solid picks to wait out more choppiness in the broad markets, especially if February follows January lower.
 
About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
 
Get the full Report on FBT – FREE
Get the full Report on MORT – FREE
Get the full Report on PGX – FREE
 
Follow us on Twitter:  http://twitter.com/ZacksResearch
 
Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch
 
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on FBT

Read the analyst report on MORT

Read the analyst report on PGX


Zacks Investment Research

View Comments (0)